ClinicalTrials.gg
TerminatedNCT01015729Updated Jan 16, 2012

Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately

A Phase 1 interventional study of Esomeprazole/ASA Fixed Combination and Esomeprazole in Peptic Ulcer Disease, sponsored by AstraZeneca. Terminated at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-01-16.

Sponsored by AstraZeneca · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate whether a fixed dose combination (FDC) capsule of esomeprazole 20 mg and acetylsalicylic acid (ASA) 81 mg has equivalent therapeutic efficacy compared to each of 2 free combinations of ASA tablet 81 mg plus esomeprazole 20 mg in patients at risk of gastrointestinal events using low dose ASA for cardiovascular protection.

02

Conditions studied

  • Peptic Ulcer Disease

Browse trials for

Keywords

  • Bioequivalence
  • ASA
  • Esomeprazole
  • peptic ulcer disease
  • pH measurements
03

In context

Peptic Ulcer

146 studies on the registry are indexed under Peptic Ulcer; 25 are open to participants now.

This study's enrollment of 30 is below the median of 165 across 105 interventional studies indexed under Peptic Ulcer.

Browse Peptic Ulcer studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoking male and female subjects, aged 18 years or older with a documented history of uncomplicated peptic ulcer(s), or aged 65 years or older
  • (BMI = weight/height2) greater than or equal to 18.5 kg/m2 and less than or equal to 35.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Known history of to esomeprazole (e.g. Nexium®) or related drugs such as omeprazole (e.g. Losec®, Prilosec®), lansoprazole (e.g. Prevacid®, Hp-PAC®), pantoprazole (e.g. Pantoloc®, PANTO® IV), or rabeprazole (e.g. Pariet™), a known hypersensitivity to ASA (e.g. Aspirin®) and/or related drugs such as ibuprofen (e.g. Motrin®, Advil®), indomethacin (e.g. Indocin®), diclofenac (e.g. Voltaren®), naproxen (e.g. Aleve®, Naprosyn®), or ketoprofen (e.g. Rhovail®).
  • Significant history of pulmonary, endocrine, musculoskeletal, neurological, hematological, liver or kidney disease, or gastrointestinal disease (with the exception of uncomplicated peptic ulcer), unless deemed NCS by the Principal Investigator or Sub-investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    1

    Esomeprazole 20 mg/ASA 81 mg Fixed Dose Combination Capsule

    Drug: Esomeprazole/ASA Fixed Combination

  • Active comparator
    2

    Esomeprazole Clinical Trial Capsule 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg

    Drug: Esomeprazole · Drug: ASA

  • Active comparator
    3

    Esomeprazole MUPS Tablet 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg

    Drug: Esomeprazole · Drug: ASA

Interventions

  • DrugEsomeprazole/ASA Fixed Combination

    Capsule, oral, single dose

  • oral, single dose

    Also known as: Nexium

  • DrugASA

    Tablet, oral, single dose

    Also known as: Aspirin

06

What researchers measure

Primary outcomes

  1. Percentage of time that intragastric pH is maintained > 4.0 during the 24-hour recording period

    Time frame: pH is measured over a 24-hour period following dosing on Day 5 after repeated oral administartion/dosing

Secondary outcomes

  1. Percentage of time that intragastric pH is maintained > 3.0 during the 24-hour recording period

    Time frame: pH is measured over a 24-hour period following dosing on Day 5 after repeated oral administartion/dosing

  2. Median 24-hour intragastric pH

    Time frame: pH is measured over a 24-hour period following dosing on Day 5 after repeated oral administartion/dosing

  3. Gastrointestinal symptom (Global Overall Symptoms questionnaire)

    Time frame: GOS questionnaire will be adminsited on day 5

07

Study locations

1 site
  • Research Site
    Scarborough, Ontario, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2009
First posted
Nov 18, 2009
Start
Nov 2009
CompletionActual
Mar 2010
Last update
Jan 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01015729
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 18, 2009
Start date
Nov 2009
Completion
Mar 2010
Last update
Jan 16, 2012

Study contacts

TJorgen Nasdal, MD, PhD
study director · AstraZeneca R&D
Pierre Geoffroy, M.D. C.M., M.Sc., F.C.F.P.
principal investigator · Biovail Contract Research (BCR)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Esomeprazole · Aspirin

Start the discussion